Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current effort
Dear Fellow Shareholders of Nutra Pharma:
As we are getting close to the end of the year, I wanted to take this opportunity to update you on the current status of the Company, provide a review of 2017 and briefly outline our goals and expectations for the coming months.
Nutra Pharma Corporation operates as a biotechnology and biopharmaceutical company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, autoimmune disorders, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. We announced last year that we had hired Dr. Dale Vander Putten as our new Chief Scientific Officer to move our clinical trial platform forward; focusing primarily on RPI-78M for the treatment of Pediatric Multiple Sclerosis under the Orphan Designation that was granted in 2016. Orphan designation will greatly reduce the cost and time to bring RPI-78M through the FDA process.
Throughout this year, we have accomplished the following:
We were featured in television news segments that ran nationally on NBC news from the NBC-Miami station and internationally on the Spanish language show, Primero Impacto.
We announced a collaboration with the International Security Group to investigate the use of our technology as a counter measure against nerve agents.
We announced a collaboration with the University of Maryland Bioprocess Scale-Up Facility (BSF) to optimize manufacturing processes for the production of RPI-78M for the planned upcoming clinical trials in Pediatric Multiple Sclerosis.
We launched Luxury Feet, a new version and packaging of our OTC pain drug, Nyloxin, specifically marketed for the treatment and prevention of pain and discomfort that women experience from wearing high heels.
We announced that the textbook, Multimodal Management of Canine Osteoarthritis, Second Edition, includes references to Nutra Pharma's development of cobra venom-based products for treating pain in dogs; directly supporting Pet Pain-Away.
It has been years since we were able to make progress with our therapeutic drug pipeline; arguably the most significant property at Nutra Pharma. With the Orphan designation, we are now able to move back into clinical trials relatively quickly and at a fraction of the expected costs. We had expected to begin this process in 2017, but were delayed due to market conditions and a lack of funding. Regardless of these issues, we were still able to lay the groundwork for the eventual drug production and trial protocol development. It is our goal to complete the Phase I/II trials in pediatric MS over the next 18-24 months and then either move into Phase III trials or seek a licensing partner.
Throughout 2018, we expect to continue actively marketing Nyloxin® and Pet Pain-Away™ as well as beginning sales of Nyloxin® Military Strength. It is our goal to begin broad retail sales of our OTC products and get Nyloxin® and Pet Pain-Away into retail stores by the end of 2018. These sales will bring in the revenue that will bring the company to profitability as well as provide the financing for the proposed clinical studies. We have worked diligently with our partners to move the registration process forward in Canada. We have also worked with distributors in Mexico, Spain, Israel, Singapore, Australia and New Zealand. Most of these markets should provide revenue growth throughout 2018.
At the same time, we will get back into clinical trials for our lead drug candidates, RPI-MN and RPI-78M. As we move these processes forward, we will keep you informed as to our progress. As we have always stated, it is our eventual goal over the next several years to market or license our drugs for the treatment of Multiple Sclerosis and HIV/AIDS. This represents the true potential of Nutra Pharma as a Bio-Pharmaceutical company.
We have had a lot of false starts over the past few years. We have had necessary financing that resulted in the reduction of share value and stock dilution. We believe that 2018 will see the end of these issues. Sales growth and marketing expansion will allow for a better market for our products and services. Marketing partnership will bring in strategic investors with a vested interest in the future of our Company. This will make 2018 our best year ever – for our shareholders, our customers and our patients.
If you haven’t already taken a moment to sign up for our e-mail alerts, be sure to do so by visiting our website. Signing up will ensure that you receive the latest news and announcements when they become available. As always, if you have any additional questions or would like more information, please contact our investor relations’ hotline at (877) 895-5647.
Rik J. Deitsch
Chairman and Chief Executive Officer
Nutra Pharma Corporation; Stock Symbol: NPHC
This letter contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). This shareholder letter should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this shareholder letter and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.